Cargando…
Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study
BACKGROUND: Large-scale comparative research exploring the risk after the third dose and after inactivated covid-19 vaccination is limited. This study aimed to assess the risk of carditis following three doses of BNT162b2 or CoronaVac. METHODS: We conducted a self-controlled case series (SCCS) and a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039395/ https://www.ncbi.nlm.nih.gov/pubmed/37360861 http://dx.doi.org/10.1016/j.lanwpc.2023.100745 |
_version_ | 1784912259156279296 |
---|---|
author | Fan, Min Lai, Francisco Tsz Tsun Cheng, Franco Wing Tak Tsie, Natalie Tsz Ying Li, Xue Wan, Eric Yuk Fai Wong, Carlos King Ho Chan, Esther Wai Yin Yiu, Kai Hang Wong, Ian Chi Kei Chui, Celine Sze Ling |
author_facet | Fan, Min Lai, Francisco Tsz Tsun Cheng, Franco Wing Tak Tsie, Natalie Tsz Ying Li, Xue Wan, Eric Yuk Fai Wong, Carlos King Ho Chan, Esther Wai Yin Yiu, Kai Hang Wong, Ian Chi Kei Chui, Celine Sze Ling |
author_sort | Fan, Min |
collection | PubMed |
description | BACKGROUND: Large-scale comparative research exploring the risk after the third dose and after inactivated covid-19 vaccination is limited. This study aimed to assess the risk of carditis following three doses of BNT162b2 or CoronaVac. METHODS: We conducted a self-controlled case series (SCCS) and a case–control study using electronic health and vaccination records in Hong Kong. Carditis incidents within 28 days of covid-19 vaccination were included as cases. In the case–control study, up to 10 hospitalized controls were selected with stratified probability sampling by age, sex, and hospital admission (±1 day). The incidence rate ratios (IRRs) were reported from conditional Poisson regressions for SCCS, and adjusted odds ratios (ORs) were reported from multivariable logistic regressions. FINDINGS: A total of 8,924,614 doses of BNT162b2 and 6,129,852 doses of CoronaVac were administered from February 2021 to March 2022. The SCCS detected increased carditis risks after BNT162b2: 4.48 (95%confidence interval [CI]:2.99–6.70] in 1–14 days and 2.50 (95%CI:1.43–4.38) in 15–28 days after first dose; 10.81 (95%CI:7.63–15.32) in 1–14 days and 2.95 (95%CI:1.82–4.78) in 15–28 days after second dose; 4.72 (95%CI:1.40–15.97) in 1–14 days after third dose. Consistent results were observed from the case–control study. Risks were specifically found in people aged below 30 years and males. No significant risk increase was observed after CoronaVac in all primary analyses. INTERPRETATIONS: We detected increased carditis risks within 28 days after all three doses of BNT162b2 but the risk after the third doses were not higher than that of the second dose when compared with baseline period. Continuous monitoring of carditis after both mRNA and inactivated covid-19 vaccines is needed. FUNDING: : This study was funded by Hong Kong 10.13039/501100005407Health Bureau (COVID19F01). |
format | Online Article Text |
id | pubmed-10039395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100393952023-03-27 Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study Fan, Min Lai, Francisco Tsz Tsun Cheng, Franco Wing Tak Tsie, Natalie Tsz Ying Li, Xue Wan, Eric Yuk Fai Wong, Carlos King Ho Chan, Esther Wai Yin Yiu, Kai Hang Wong, Ian Chi Kei Chui, Celine Sze Ling Lancet Reg Health West Pac Articles BACKGROUND: Large-scale comparative research exploring the risk after the third dose and after inactivated covid-19 vaccination is limited. This study aimed to assess the risk of carditis following three doses of BNT162b2 or CoronaVac. METHODS: We conducted a self-controlled case series (SCCS) and a case–control study using electronic health and vaccination records in Hong Kong. Carditis incidents within 28 days of covid-19 vaccination were included as cases. In the case–control study, up to 10 hospitalized controls were selected with stratified probability sampling by age, sex, and hospital admission (±1 day). The incidence rate ratios (IRRs) were reported from conditional Poisson regressions for SCCS, and adjusted odds ratios (ORs) were reported from multivariable logistic regressions. FINDINGS: A total of 8,924,614 doses of BNT162b2 and 6,129,852 doses of CoronaVac were administered from February 2021 to March 2022. The SCCS detected increased carditis risks after BNT162b2: 4.48 (95%confidence interval [CI]:2.99–6.70] in 1–14 days and 2.50 (95%CI:1.43–4.38) in 15–28 days after first dose; 10.81 (95%CI:7.63–15.32) in 1–14 days and 2.95 (95%CI:1.82–4.78) in 15–28 days after second dose; 4.72 (95%CI:1.40–15.97) in 1–14 days after third dose. Consistent results were observed from the case–control study. Risks were specifically found in people aged below 30 years and males. No significant risk increase was observed after CoronaVac in all primary analyses. INTERPRETATIONS: We detected increased carditis risks within 28 days after all three doses of BNT162b2 but the risk after the third doses were not higher than that of the second dose when compared with baseline period. Continuous monitoring of carditis after both mRNA and inactivated covid-19 vaccines is needed. FUNDING: : This study was funded by Hong Kong 10.13039/501100005407Health Bureau (COVID19F01). Elsevier 2023-03-25 /pmc/articles/PMC10039395/ /pubmed/37360861 http://dx.doi.org/10.1016/j.lanwpc.2023.100745 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Fan, Min Lai, Francisco Tsz Tsun Cheng, Franco Wing Tak Tsie, Natalie Tsz Ying Li, Xue Wan, Eric Yuk Fai Wong, Carlos King Ho Chan, Esther Wai Yin Yiu, Kai Hang Wong, Ian Chi Kei Chui, Celine Sze Ling Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study |
title | Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study |
title_full | Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study |
title_fullStr | Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study |
title_full_unstemmed | Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study |
title_short | Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study |
title_sort | risk of carditis after three doses of vaccination with mrna (bnt162b2) or inactivated (coronavac) covid-19 vaccination: a self-controlled cases series and a case–control study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039395/ https://www.ncbi.nlm.nih.gov/pubmed/37360861 http://dx.doi.org/10.1016/j.lanwpc.2023.100745 |
work_keys_str_mv | AT fanmin riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT laifranciscotsztsun riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT chengfrancowingtak riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT tsienatalietszying riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT lixue riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT wanericyukfai riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT wongcarloskingho riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT chanestherwaiyin riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT yiukaihang riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT wongianchikei riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy AT chuicelineszeling riskofcarditisafterthreedosesofvaccinationwithmrnabnt162b2orinactivatedcoronavaccovid19vaccinationaselfcontrolledcasesseriesandacasecontrolstudy |